To read the full story, subscribe or sign in.

Alterity’s ATH-434 looks to be disease modifying in multiple system atrophy

Jan. 30, 2025

Alterity Therapeutics Ltd. reported positive top-line phase II results for lead candidate ATH-434 for treating multiple system atrophy, a rare neurological disorder similar to Parkinson's disease.

BioWorld Clinical Musculoskeletal Neurology/psychiatric Small molecule Asia-Pacific U.S. FDA

Today's news in brief

BioWorld

BioWorld briefs for March 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 4, 2025

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...